SCHEMBL4876765

SCHEMBL4876765

CN(Cc1ccccc1)S(=O)(=O)C(N)=O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
CA12 O43570 1/20 0.49
CA9 Q16790 1/20 0.49
CA2 P00918 1/20 0.47
AOC3 Q16853 1/20 0.47
ALDH1A1 P00352 3/20 0.46
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
LMNA P02545 1/20 0.46
MMP3 P08254 1/20 0.46
TSHR P16473 2/20 0.45
HDAC4 P56524 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
CXCR4 P61073 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7478269 0.79 MMP3 (0.57) KMT2AMEN1NPC1RAB9ACA12
SCHEMBL5655809 0.77 ALDH1A1 (0.52) KMT2AMEN1NPC1RAB9ACA12
SCHEMBL1243447 0.77 CA2 (0.64) KMT2AMEN1NPC1RAB9ACA12
SCHEMBL15067400 0.76 ALDH1A1 (0.44) KMT2AMEN1NPC1RAB9ACA12
SCHEMBL15067398 0.76 ALDH1A1 (0.44) KMT2AMEN1NPC1RAB9ACA12
SCHEMBL7475586 0.75 MMP3 (0.60) KMT2AMEN1NPC1RAB9ACA12
SCHEMBL6629548 0.75 ALDH1A1 (0.54) KMT2AMEN1NPC1RAB9ACA12
Urea SCHEMBL28073648 0.75 ALDH1A1 (0.74) KMT2AMEN1NPC1RAB9ACA12
Carbamic Acid SCHEMBL30426064 0.75 ALDH1A1 (0.74) KMT2AMEN1NPC1RAB9ACA12
SCHEMBL2057187 0.75 ALDH1A1 (0.54) KMT2AMEN1NPC1RAB9ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096922-A1 Novel Sulfonamide derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-04-24 US disclosed
EP-1736467-A1 NOVEL SULFONAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096922-A1 Novel Sulfonamide derivative NR4A1, NR4A2, NR4A3 KMT2A 1132/4885MEN1 3740/4885NPC1 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.